# C4 Therapeutics, Inc.: financial statements, quarterly

CCCC · Nasdaq · CIK 1662579 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cccc.md) · [Financials](/companies/cccc/financials.md) · [Filings](/companies/cccc/filings.md) · [Insiders](/companies/cccc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cccc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q1 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.1](/filings/0001628280-24-044411.md) | [3.3 d](/filings/0001628280-25-008433.md) | [3.0](/filings/0001628280-25-022866.md) | [12.0](/filings/0001628280-25-038587.md) | [15.4](/filings/0001628280-25-049854.md) | [5.2 d](/filings/0001628280-26-012000.md) | [7.2](/filings/0001628280-26-033865.md) | [6.5](/filings/0001628280-26-055494.md) | [11.2](/filings/0001628280-25-049854.md) | [11.0 d](/filings/0001628280-26-012000.md) | [6.2](/filings/0001628280-26-033865.md) | [6.6](/filings/0001628280-26-055494.md) |
| Research and development | $m | [28.3](/filings/0001628280-24-044411.md) | [30.4 d](/filings/0001628280-25-008433.md) | [22.5](/filings/0001628280-25-022866.md) | [23.8](/filings/0001628280-25-038587.md) | [31.8](/filings/0001628280-25-049854.md) | [32.5 d](/filings/0001628280-26-012000.md) | [27.1](/filings/0001628280-26-033865.md) | [26.2](/filings/0001628280-26-055494.md) | [26.0](/filings/0001628280-25-049854.md) | [25.0 d](/filings/0001628280-26-012000.md) | [24.6](/filings/0001628280-26-033865.md) | [24.5](/filings/0001628280-26-055494.md) |
| Operating income | $m | [(27.8)](/filings/0001628280-24-044411.md) | [(37.4) d](/filings/0001628280-25-008433.md) | [(32.2)](/filings/0001628280-25-022866.md) | [(21.4)](/filings/0001628280-25-038587.md) | [(28.2)](/filings/0001628280-25-049854.md) | [(37.7) d](/filings/0001628280-26-012000.md) | [(29.2)](/filings/0001628280-26-033865.md) | [(28.5)](/filings/0001628280-26-055494.md) | [(34.4)](/filings/0001628280-25-049854.md) | [(23.1) d](/filings/0001628280-26-012000.md) | [(27.8)](/filings/0001628280-26-033865.md) | [(26.4)](/filings/0001628280-26-055494.md) |
| Income tax | $m | [1.0](/filings/0001628280-24-044411.md) | [0.3 d](/filings/0001628280-25-008433.md) | [0.0](/filings/0001628280-25-022866.md) | [0.0](/filings/0001628280-25-038587.md) | [0.0](/filings/0001628280-25-049854.md) | [0.1 d](/filings/0001628280-26-012000.md) | [0.0](/filings/0001628280-26-033865.md) | [0.0](/filings/0001628280-26-055494.md) | [0.0](/filings/0001628280-25-049854.md) | [0.1 d](/filings/0001628280-26-012000.md) | [0.0](/filings/0001628280-26-033865.md) | [0.0](/filings/0001628280-26-055494.md) |
| Net income | $m | [(27.0)](/filings/0001628280-24-044411.md) | [(34.8) d](/filings/0001628280-25-008433.md) | [(28.4)](/filings/0001628280-25-049854.md) | [(17.7)](/filings/0001628280-25-049854.md) | [(24.7)](/filings/0001628280-25-049854.md) | [(34.6) d](/filings/0001628280-26-012000.md) | [(26.3)](/filings/0001628280-26-055494.md) | [(26.0)](/filings/0001628280-26-055494.md) | [(32.2)](/filings/0001628280-25-049854.md) | [(20.5) d](/filings/0001628280-26-012000.md) | [(25.1)](/filings/0001628280-26-055494.md) | [(23.6)](/filings/0001628280-26-055494.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0001628280-24-044411.md) | not reported | [(0.41)](/filings/0001628280-25-022866.md) | [(0.26)](/filings/0001628280-25-038587.md) | [(0.35)](/filings/0001628280-25-049854.md) | not reported | [(0.37)](/filings/0001628280-26-033865.md) | [(0.37)](/filings/0001628280-26-055494.md) | [(0.44)](/filings/0001628280-25-049854.md) | not reported | [(0.20)](/filings/0001628280-26-033865.md) | [(0.18)](/filings/0001628280-26-055494.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0001628280-24-044411.md) | not reported | [(0.41)](/filings/0001628280-25-022866.md) | [(0.26)](/filings/0001628280-25-038587.md) | [(0.35)](/filings/0001628280-25-049854.md) | not reported | [(0.37)](/filings/0001628280-26-033865.md) | [(0.37)](/filings/0001628280-26-055494.md) | [(0.44)](/filings/0001628280-25-049854.md) | not reported | [(0.20)](/filings/0001628280-26-033865.md) | [(0.18)](/filings/0001628280-26-055494.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q1 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [61.0](/filings/0001628280-24-044411.md) | [127](/filings/0001628280-25-008433.md) | [89.7](/filings/0001628280-25-022866.md) | [73.1](/filings/0001628280-25-038587.md) | [59.6](/filings/0001628280-25-049854.md) | [55.5](/filings/0001628280-26-012000.md) | [51.3](/filings/0001628280-26-033865.md) | [78.2](/filings/0001628280-26-055494.md) | [58.8](/filings/0001628280-25-049854.md) | [74.6](/filings/0001628280-26-055494.md) | [61.3](/filings/0001628280-26-033865.md) | [78.6](/filings/0001628280-26-055494.md) |
| Current assets | $m | [224](/filings/0001628280-23-035793.md) | [271](/filings/0001628280-25-008433.md) | [280](/filings/0001628280-24-021368.md) | [276](/filings/0001628280-24-033882.md) | [273](/filings/0001628280-24-044411.md) | [258](/filings/0001628280-26-012000.md) | [233](/filings/0001628280-25-022866.md) | [225](/filings/0001628280-25-038587.md) | [207](/filings/0001628280-25-049854.md) | [258](/filings/0001628280-26-055494.md) | [245](/filings/0001628280-26-033865.md) | [263](/filings/0001628280-26-055494.md) |
| Total assets | $m | [333](/filings/0001628280-23-035793.md) | [376](/filings/0001628280-25-008433.md) | [398](/filings/0001628280-24-021368.md) | [381](/filings/0001628280-24-033882.md) | [376](/filings/0001628280-24-044411.md) | [350](/filings/0001628280-26-012000.md) | [320](/filings/0001628280-25-022866.md) | [297](/filings/0001628280-25-038587.md) | [265](/filings/0001628280-25-049854.md) | [359](/filings/0001628280-26-055494.md) | [329](/filings/0001628280-26-033865.md) | [359](/filings/0001628280-26-055494.md) |
| Current liabilities | $m | [30.3](/filings/0001628280-23-035793.md) | [42.8](/filings/0001628280-25-008433.md) | [55.0](/filings/0001628280-24-021368.md) | [54.2](/filings/0001628280-24-033882.md) | [43.3](/filings/0001628280-24-044411.md) | [45.2](/filings/0001628280-26-012000.md) | [40.8](/filings/0001628280-25-022866.md) | [44.5](/filings/0001628280-25-038587.md) | [35.9](/filings/0001628280-25-049854.md) | [33.0](/filings/0001628280-26-055494.md) | [27.2](/filings/0001628280-26-033865.md) | [48.2](/filings/0001628280-26-055494.md) |
| Total liabilities | $m | [117](/filings/0001628280-23-035793.md) | [130](/filings/0001628280-25-008433.md) | [140](/filings/0001628280-24-021368.md) | [134](/filings/0001628280-24-033882.md) | [133](/filings/0001628280-24-044411.md) | [134](/filings/0001628280-26-012000.md) | [124](/filings/0001628280-25-022866.md) | [122](/filings/0001628280-25-038587.md) | [111](/filings/0001628280-25-049854.md) | [102](/filings/0001628280-26-055494.md) | [94.6](/filings/0001628280-26-033865.md) | [112](/filings/0001628280-26-055494.md) |
| Long-term debt | $m | [0.0](/filings/0001628280-23-035793.md) | [0.0](/filings/0001628280-24-006144.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.0](/filings/0001628280-23-035793.md) | [0.0](/filings/0001628280-24-006144.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [216](/filings/0001628280-24-044411.md) | [246](/filings/0001628280-26-012000.md) | [258](/filings/0001628280-25-049854.md) | [247](/filings/0001628280-25-049854.md) | [243](/filings/0001628280-25-049854.md) | [216](/filings/0001628280-26-055494.md) | [195](/filings/0001628280-26-055494.md) | [174](/filings/0001628280-26-055494.md) | [154](/filings/0001628280-25-049854.md) | [257](/filings/0001628280-26-055494.md) | [234](/filings/0001628280-26-055494.md) | [247](/filings/0001628280-26-055494.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(30.7) d](/filings/0001628280-24-044411.md) | [(24.0) d](/filings/0001628280-25-008433.md) | [(18.1)](/filings/0001628280-25-022866.md) | [(5.0) d](/filings/0001628280-25-038587.md) | [(24.1) d](/filings/0001628280-25-049854.md) | [(17.9) d](/filings/0001628280-26-012000.md) | [(33.3)](/filings/0001628280-26-033865.md) | [(12.1) d](/filings/0001628280-26-055494.md) | [(31.2) d](/filings/0001628280-25-049854.md) | [(22.1) d](/filings/0001628280-26-012000.md) | [(29.9)](/filings/0001628280-26-033865.md) | [(1.6) d](/filings/0001628280-26-055494.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001628280-24-044411.md) | [0.2 d](/filings/0001628280-25-008433.md) | [0.0](/filings/0001628280-24-021368.md) | [0.2 d](/filings/0001628280-25-038587.md) | [(0.0) d](/filings/0001628280-25-049854.md) | [(0.0) d](/filings/0001628280-26-012000.md) | [0.0](/filings/0001628280-26-033865.md) | [0.2 d](/filings/0001628280-26-055494.md) | [0.4 d](/filings/0001628280-25-049854.md) | [0.0 d](/filings/0001628280-26-012000.md) | [0.1](/filings/0001628280-26-033865.md) | [0.0 d](/filings/0001628280-26-055494.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-044411.md) | [0.0 d](/filings/0001628280-25-008433.md) | [0.1](/filings/0001628280-25-022866.md) | [0.0 d](/filings/0001628280-25-038587.md) | [0.1 d](/filings/0001628280-25-049854.md) | [0.0 d](/filings/0001628280-26-012000.md) | [0.2](/filings/0001628280-26-033865.md) | [0.0 d](/filings/0001628280-26-055494.md) | [0.0 d](/filings/0001628280-25-049854.md) | [0.0 d](/filings/0001628280-26-012000.md) | [0.2](/filings/0001628280-26-033865.md) | [0.0 d](/filings/0001628280-26-055494.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q1 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q1 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.9](/filings/0001628280-23-035793.md) | [49.0](/filings/0001628280-24-021368.md) | [49.1](/filings/0001628280-24-033882.md) | [49.2](/filings/0001628280-24-044411.md) | [68.4](/filings/0001628280-25-022866.md) | [68.8](/filings/0001628280-25-038587.md) | [69.6](/filings/0001628280-25-049854.md) | [70.8](/filings/0001628280-26-033865.md) | [71.0](/filings/0001628280-26-055494.md) | [72.6](/filings/0001628280-25-049854.md) | [126](/filings/0001628280-26-033865.md) | [131](/filings/0001628280-26-055494.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 123,025,136 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001628280-26-055494.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.